IMPORTANT INVESTOR ALERT: JFJN LAW Announces Securities Class Action Lawsuit Against DaVita Inc.
March 16 2017 - 1:28PM
Business Wire
JFJN Law (the “firm) announces the filing of a class action
lawsuit against DaVita Inc. (“DaVita” or the “Company”) (NYSE:DVA).
Investors who purchased or otherwise acquired shares between
August 5, 2015 and October 21, 2016 inclusive (the “Class
Period”) are encouraged to contact the Firm in advance of the April
3, 2017 lead plaintiff motion deadline.
If you purchased shares of DaVita during the Class Period,
please contact Justin Frankel, Esq., of JFJN Law, 1-888-459-0507 or
jcf@jfjnclassaction.com before April 3, 2017.
There has not been a class certification of this case yet. Until
certification occurs, you are not represented by an attorney. You
may take no action and remain a passive class member.
DaVita provides kidney dialysis services for patients suffering
from chronic kidney failure or end-stage renal disease (“ESRD”).
The Company made contributions to the American Kidney Fund (“AKF”)
a not for profit organization that offers financial assistance for
kidney dialysis patients.
On August 18, 2016, The Centers for Medicare & Medicaid
Services (“CMS”) issued a public request for information regarding
alleged steering of Medicare and Medicaid beneficiaries into other
plans in order to earn higher reimbursement rates. In reaction to
the disclosure about the CMS inquiry into the industry and the
potential rule changes, DaVita’s stock price dropped.
DaVita’s stock dropped further following an article in The St.
Louis Post (October 23, 2016) that accused DaVita of steering
clients to private insurers and using its own money to pay for
health insurance premiums through the American Kidney
Foundation.
On January 6, 2017 The Wall Street Journal reported that DaVita
had received subpoenas from federal prosecutors for “the production
of information related to charitable premium assistance” regarding
the company’s relationship with the American Kidney Fund. The value
of DaVita stock fell when this information became public, causing
investors harm.
Throughout the Class Period, Defendants made false and/or
misleading statements, and/or failed to disclose material adverse
facts about the Company’s business, operations, and prospects.
If you have any questions about this notice, or wish to learn
more about this class action lawsuit, contact Justin Frankel, Esq.,
by phone at 1-888-459-0507 or by email jcf@jfjnclassaction.com
before April 3, 2017.
This press release may be considered Attorney Advertising in
some jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170316006062/en/
JFJN LawJustin C. Frankel, Esq.Toll-Free Telephone:
1-888-459-0507Telephone: 516-493-9420Facsimile:
516-493-9421jcf@jfjnclassaction.com
DaVita (NYSE:DVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Sep 2023 to Sep 2024